A clinical study of bojungikgitang and banhabaekchulchonmatang in adult tinnitus patients
ISRCTN | ISRCTN23691284 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN23691284 |
Secondary identifying numbers | B08-0045-AM0829-08N1-00010A |
- Submission date
- 25/05/2009
- Registration date
- 05/06/2009
- Last edited
- 29/07/2010
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Ear, Nose and Throat
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Donghyo Lee
Scientific
Scientific
Wonkwang University Oriental Medical Center
1126-1 Sanbon-dong
Gunpo
435-040
Korea, South
secretop17@naver.com |
Study information
Study design | Randomised phase III double-blind three-arm placebo-controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Participant information sheet | Not available in web format, please use the contact details below to request a patient information sheet |
Scientific title | A clinical study of bojungikgitang and banhabaekchulchonmatang in adult tinnitus patients: a randomised, double-blind, three-arm, placebo-controlled trial |
Study objectives | This study is aimed to evaluate the efficacy and safety of bojungikgitang and banhabaekchulchonmatang in adult tinnitus patients. |
Ethics approval(s) | Wonkwang University Oriental Medical Center Ethics Committee gave approval on the 25th February 2009 |
Health condition(s) or problem(s) studied | Tinnitus |
Intervention | This study is a randomised, double-blind, placebo-controlled study. Participants will receive bojungikgitang, banhabaekchulchonmatang, or a placebo-drug for 8 weeks. Oral administration occurs according to the following statements: 1. Patients in group 1 receive bojungikgitang and instructions on how to make a tea; they take a packet of the medicine (12.52 g) with tepid water for three times a day after meal 2. Patients in group 2 receive banhabaekchulchonmatang and instructions on how to make a tea; they take a packet of the medicine (12.52 g) with tepid water for three times a day after meal 3. Patients in group 3 receive the placebo medicine (powdered extract), used in the same way as with group 1 and 2 The total duration of all arms is 11 weeks. Timepoints are as follows: Visit 1: screening Visit 2: treatment initiation, participants will receive bojungikgitang, banhabaekchulchonmatang, or a placebo-drug for 8 weeks Visit 3: 4 weeks later of first medication, follow-up Visit 4: 8 weeks later of first medication, follow-up and treatment finish Visit 5: 10 weeks later of first medication, follow-up |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Phase III |
Drug / device / biological / vaccine name(s) | Bojungikgitang, banhabaekchulchonmatang |
Primary outcome measure | Efficacy: Tinnitus Handicap Inventory (THI): the purpose of this questionnaire is to identify difficulties that may be experienced because of tinnitus: 1.1. F: Functional subscale (11 factors) 1.2. E: Emotional subscale (9 factors) 1.3. C: Catastrophic subscale (5 factors) Measured at baseline (1 week before treatment initiation), 4 weeks later of the first medication, 8 weeks later of the first medication, follow up (2 weeks later of treatment period) Safety: 1. Complete blood cell count, erythrocyte sedimentation rate (ESR) 2. Blood chemistry 3. Urine analysis 4. Chest antero-posterior (PA) film Measured at baseline, 8 weeks later of the first medication 5. Brain computed tomography (CT) 6. Otologic examination Measured at baseline 7. Vital signs; measured at baseline, treatment initiation, 4 weeks later of the first medication, 8 weeks later of the first medication |
Secondary outcome measures | Efficacy: 1. Acoustic Examination (AE) 2. Visual Analogue Scale (VAS) Measured at baseline (1 week before treatment initiation), 4 weeks later of the first medication, 8 weeks later of the first medication, follow up (2 weeks later of treatment period) 3. EQ-5D 4. Health Utilities Index Mark 3 (HUI3) Measured at baseline, 8 weeks later of the first medication, follow up |
Overall study start date | 01/03/2009 |
Completion date | 30/09/2009 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Adult |
Sex | Both |
Target number of participants | 120 |
Key inclusion criteria | 1. Age greater than 19 years, either sex 2. Typical conditions of intermittent or continuous tinnitus 2.1. The duration of more than 3 months 2.2. Involuntary perception of the concept of a sound without the presence of an external source 3. Agreed not to receive another treatment during the clinical trial period 4. Written and informed consent |
Key exclusion criteria | 1. Receiving other forms of tinnitus treatments 2. Underlying disease or history: 2.1. Otitis media 2.2. Acoustic tumour 2.3. Intracranial lesion 2.4. Inner ear malformation 2.5. Head trauma 2.6. Ototoxic drug medication, etc. 3. Women in pregnacy and lactation or without contraception 4. Other clinical trial within the last 1 month 5. Auditory surgery, a major surgery or a blood transfusion within the last 1 month 6. Hypersensitiveness or allergy of drugs 7. Disease which can affect the absorption of drugs or disordered digestion after surgery related to the disease 8. History of neuropsychitric abnormality: 8.1. Manic-depression 8.2. Schizophrenia 8.3. Alcoholism 8.4. Drug addiction, etc. 9. Cannot understand a written consent or follow this study: 9.1. Mental retardation 9.2. Mental or emotional problems 10. Judged by expert that they are inappropriate to participate in this study |
Date of first enrolment | 01/03/2009 |
Date of final enrolment | 30/09/2009 |
Locations
Countries of recruitment
- Korea, South
Study participating centre
Wonkwang University Oriental Medical Center
Gunpo
435-040
Korea, South
435-040
Korea, South
Sponsor information
Korea Health Industry Development Institute (KHIDI) (South Korea)
Research organisation
Research organisation
57-1 Noryangjin-dong
Dongjak-gu
Seoul
158-800
Korea, South
Phone | +82 (0)2 2194 7227 |
---|---|
withingrace@khidi.or.kr | |
Website | http://eng.khidi.or.kr/ |
https://ror.org/00fdzyk40 |
Funders
Funder type
Research organisation
Korea Health Industry Development Institute (KHIDI) (South Korea) - The 2008 Traditional Korean Medicine Research and Development Project
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Protocol article | protocol | 28/03/2010 | Yes | No |